{"DataElement":{"publicId":"2626164","version":"1","preferredName":"Prior Anthracycline Therapy Regimen Ind-2","preferredDefinition":"the yes/no indicator that asks whether there was a prior anthracycline therapy regimen.","longName":"PRI_ANTH_TX_RGM_IND2","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2626153","version":"1","preferredName":"Prior Anthracycline Therapy Regimen","preferredDefinition":"information relating to a prior anthracycline (a member of a family of anticancer drugs that are also antibiotics) treatment regimen.","longName":"PRIOR_ANTH_TX_RGM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2626151","version":"1","preferredName":"Prior Anthracycline Antibiotic Therapy","preferredDefinition":"Earlier in time or order.:A member of a family of anticancer drugs that are also antibiotics.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C25629:C1594:C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Anthracycline Antineoplastic Antibiotic","conceptCode":"C1594","definition":"An antineoplastic antibiotic that is structurally similar to the benzoquinone ansamycin antibiotic geldanamycin. A geldanamycin analogue binds to HSP90, a chaperone protein that aids in the assembly, maturation, and folding of proteins. Subsequently, the function of HSP90 is inhibited, leading to the degradation and depletion of client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DC589E7-9B7A-5E1A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-04-10","modifiedBy":"ONEDATA","dateModified":"2007-04-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2224042","version":"1","preferredName":"Treatment_Regimen","preferredDefinition":"Treatment schedule for the pre-clinical trial / therapeutic experiment describing the dosages of the drug and the times of the treatment.","longName":"C15697","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63F046F-540F-4E81-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-03","endDate":null,"createdBy":"UMLLOADER_CAMOD","dateCreated":"2005-05-03","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DC589E7-9B88-5E1A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-11","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-04-10","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"},{"publicId":"2811954","version":"1","longName":"Eligibility Criteria","context":"CTEP"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104903","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"10000427","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"10000426","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"10000430","version":"1","longName":"GOG-0186I","context":"NRG"},{"publicId":"10000429","version":"1","longName":"GOG-0186I","context":"NRG"},{"publicId":"4104905","version":"1","longName":"GOG-0186I","context":"NRG"},{"publicId":"10000081","version":"1","longName":"GOG-0186J","context":"NRG"},{"publicId":"4104906","version":"1","longName":"GOG-0186J","context":"NRG"},{"publicId":"10000082","version":"1","longName":"GOG-0186J","context":"NRG"},{"publicId":"4171061","version":"1","longName":"RTOG-1010","context":"NRG"},{"publicId":"4104891","version":"1","longName":"GOG-0229N","context":"NRG"}]}],"AlternateNames":[{"name":"PRI_ANTH_TX_RGM_IND2","type":"USED_BY","context":"CTEP"},{"name":"SWOG","type":"USED_BY","context":"SWOG"},{"name":"PANTHRA","type":"OID, SWOG","context":"SWOG"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"PRI_ANTH_TX_RGM_IND2","type":"USED_BY","context":"NRG"},{"name":"Alliance","type":"USED_BY","context":"Alliance"},{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"Theradex","type":"USED_BY","context":"Theradex"}],"ReferenceDocuments":[{"name":"Prior anthracycline Treatment","type":"Preferred Question Text","description":"Prior anthracycline Treatment","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Prior anthracycline chemotherapy","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Has the patient received prior treatment with an anthracycline?","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Has the patient had a prior anthracycline cumulative dose greater than 450 mg/m2?","url":null,"context":"CTEP"},{"name":"COG_CRF_Text_1","type":"Alternate Question Text","description":"Has patient exceeded the total lifetime cumulative dosage limitation for anthracycline","url":null,"context":"CTEP"},{"name":"Previous anthracycline","type":"Alternate Question Text","description":"Has the patient received previous anthracycline?","url":null,"context":"SWOG"},{"name":"NRG_CRf Text","type":"Alternate Question Text","description":"Has the patient received prior PLD, doxorubicin or other anthracyclines?","url":null,"context":"NRG"},{"name":"COG_CRF_Text_2","type":"Alternate Question Text","description":"Did patient have prior anthracycline (eg, doxorubicin, daunorubicin) or ifosfamide chemotherapy?","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Prior anthracycline","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Anthracycline-based therapies","url":null,"context":"CTEP"},{"name":"ECOG CRF Text 1","type":"Alternate Question Text","description":"Anthracycline exposure in the neoadjuvant setting","url":null,"context":"ECOG-ACRIN"},{"name":"COG_CRF_Text 4","type":"Alternate Question Text","description":"Does patient have a lifetime cumulative anthracycline dose of greater than or equal to 300mg/m2 DOXOrubicin equivalent without the protection of dexrazoxane (Zinecard) therapy?","url":null,"context":"COG"},{"name":"COG_CRF_Text_5","type":"Alternate Question Text","description":"Was patient exposed to DRZ at any point in time?","url":null,"context":"COG"},{"name":"CRF Text 5","type":"Alternate Question Text","description":"Did the patient have prior treatment with PLD","url":null,"context":"CTEP"},{"name":"COG_CRF_Text_6","type":"Alternate Question Text","description":"Does patient have a lifetime cumulative anthracycline dose, occurring prior to age 22, and with total dose of greater than or equal to 250mg/m2 DOXOrubicin equivalent without the protection of dexrazoxane (Zinecard) therapy?","url":null,"context":"COG"},{"name":"CRF Text 7","type":"Alternate Question Text","description":"Prior treatment with anthracyclines","url":null,"context":"CTEP"},{"name":"COG_CRF_Text_7","type":"Alternate Question Text","description":"Does patient have a lifetime cumulative anthracycline dose of greater than or equal to 250mg/m2 DOXOrubicin equivalent without the protection of dexrazoxane (Zinecard) therapy?","url":null,"context":"COG"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Does patient have a cumulative lifetime exposure (prior to study entry) of greater than 300 mg/m2 doxorubicin equivalent anthracycline?","url":null,"context":"Theradex"},{"name":"COG_CRF_Text_10","type":"Alternate Question Text","description":"Was anthracycline given with dexrazoxane?","url":null,"context":"COG"},{"name":"COG_CRF_Text_8","type":"Alternate Question Text","description":"Did the patient receive CPX-351 prior to disease confirmation?","url":null,"context":"COG"},{"name":"COG_CRF_Text_11","type":"Alternate Question Text","description":"Was dexrazoxane given with every cycle of anthracycline?","url":null,"context":"COG"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Prior treatment with anthracyclines?","url":null,"context":"NRG"},{"name":"COG_CRF_Text_9","type":"Alternate Question Text","description":"Did the patient receive any other  anthracycline prior to disease confirmation that is not listed above?","url":null,"context":"COG"},{"name":"NRG_eCRF_Text_1","type":"Alternate Question Text","description":"Has the patient had prior anthracycline exposure?","url":null,"context":"NRG"},{"name":"NRG CRF_Text 2","type":"Alternate Question Text","description":"Does the patient have history of exposure to the following cumulative doses of anthracyclines- Doxorubicin or liposomal doxorubicin greater than 500 mg/m2; Epirubicin greater than 900 mg/m2; Mitoxantrone greater than 120 mg/m2?","url":null,"context":"NRG"},{"name":"COG CRF Text 12","type":"Alternate Question Text","description":"Did the patient receive any anthracycline as part of prior therapy?","url":null,"context":"COG"},{"name":"COG CRF Text 13","type":"Alternate Question Text","description":"Did the patient receive anthracycline prior to disease confirmation?","url":null,"context":"COG"}],"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2DC762BC-7D40-000A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-04-10","modifiedBy":"KUMMEROA","dateModified":"2023-12-05","changeDescription":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":"2023.12.5 AQT added per ticket request CADSR0003157. ak 2023.9.6 AQT added per ticket request CADSR0002816. ak","unresolvedIssues":null,"deletedIndicator":"No"}}